TR200200410T2 - Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. - Google Patents
Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri.Info
- Publication number
- TR200200410T2 TR200200410T2 TR2002/00410T TR200200410T TR200200410T2 TR 200200410 T2 TR200200410 T2 TR 200200410T2 TR 2002/00410 T TR2002/00410 T TR 2002/00410T TR 200200410 T TR200200410 T TR 200200410T TR 200200410 T2 TR200200410 T2 TR 200200410T2
- Authority
- TR
- Turkey
- Prior art keywords
- matrix metalloproteinase
- compounds
- formula
- acid compounds
- compounds useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 231100000397 ulcer Toxicity 0.000 abstract 2
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061217 Infestation Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 201000007717 corneal ulcer Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formül (I) bilesikleri hayvanlarda matris metaloproteinaz enzimlerinin inhibe edilmesinde yararlidir ve baglayici dokularin parçalanmasindan kaynaklanan hastaliklari önler ve tevdi eder. Ayrica bu tip bilesiklerin, bunlari içeren farmasötik bilesimlerin hazirlanmasi için yöntemler ve çoklu skleroz, ateroskleroz plak parçalanmasi, restenoz, aort anevrizmasi, kalp rahatsizligi, periodontal hastalik, kornea ülseri, yaniklar, decubital ülserler, kronik ülserler veya yaralar, kanser metastazi, tümör anjiojenezi, osteoporoz, römatoid veya osteoartrit, böbrek hastaligi, sol ventiküler büyüme veya dokularin lökosit istilasina bagli diger oto-bagisiklik veya iltihap hastaliklari dahil matris metaloproteinazlarin yer aldigi hastaliklarin tedavisinde kullanilmasi tarif edilmektedir. FORMÜL (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14966099P | 1999-08-18 | 1999-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200200410T2 true TR200200410T2 (tr) | 2002-06-21 |
Family
ID=22531286
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/02164T TR200202164T2 (tr) | 1999-08-18 | 2000-08-10 | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. |
| TR2002/02211T TR200202211T2 (tr) | 1999-08-18 | 2000-08-10 | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri |
| TR2002/02163T TR200202163T2 (tr) | 1999-08-18 | 2000-08-10 | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri |
| TR2002/00410T TR200200410T2 (tr) | 1999-08-18 | 2000-08-10 | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/02164T TR200202164T2 (tr) | 1999-08-18 | 2000-08-10 | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. |
| TR2002/02211T TR200202211T2 (tr) | 1999-08-18 | 2000-08-10 | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri |
| TR2002/02163T TR200202163T2 (tr) | 1999-08-18 | 2000-08-10 | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6677355B1 (tr) |
| EP (1) | EP1210326B1 (tr) |
| JP (1) | JP2003507362A (tr) |
| AR (1) | AR030160A1 (tr) |
| AT (1) | ATE260251T1 (tr) |
| AU (1) | AU6764400A (tr) |
| BR (1) | BR0013390A (tr) |
| CA (1) | CA2378332A1 (tr) |
| CO (1) | CO5300407A1 (tr) |
| DE (1) | DE60008548T2 (tr) |
| DK (1) | DK1210326T3 (tr) |
| ES (1) | ES2216938T3 (tr) |
| MX (1) | MXPA01013324A (tr) |
| PE (1) | PE20010486A1 (tr) |
| PT (1) | PT1210326E (tr) |
| TR (4) | TR200202164T2 (tr) |
| UY (1) | UY26302A1 (tr) |
| WO (1) | WO2001012592A2 (tr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537514T3 (es) | 2003-04-04 | 2015-06-09 | Incyte Corporation | Composiciones, métodos y kits relacionados con la escisión de HER-2 |
| GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
| US7638513B2 (en) | 2004-06-02 | 2009-12-29 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| PE20060426A1 (es) * | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| US7488745B2 (en) * | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7504424B2 (en) * | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| KR20070032787A (ko) | 2004-07-16 | 2007-03-22 | 쉐링 코포레이션 | 염증 질환 치료용 히단토인 유도체 |
| AR059037A1 (es) * | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| PL2343286T3 (pl) | 2006-10-28 | 2015-06-30 | Methylgene Inc | Pochodne dibenzo[b,f][1,4]oksazepiny jako inhibitory deacetylazy histonowej |
| PE20090223A1 (es) * | 2007-05-04 | 2009-03-08 | Wyeth Corp | Compuestos triciclicos como inhibidores de metaloproteinasas matriciales |
| EP2346857B1 (en) | 2008-09-24 | 2019-11-27 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| US8859529B2 (en) | 2008-09-24 | 2014-10-14 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| EP2355825A2 (en) | 2008-11-10 | 2011-08-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US8541572B2 (en) | 2008-11-10 | 2013-09-24 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| EP2373311A1 (en) * | 2008-12-05 | 2011-10-12 | InterMed Discovery GmbH | Inhibitors of hif-1 protein accumulation |
| US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
| CN113336670B (zh) * | 2021-05-28 | 2023-06-02 | 河南大学 | 一种轴手性芴胺-苯酚类衍生物及其制备方法 |
| KR20240069638A (ko) | 2022-11-11 | 2024-05-20 | 주식회사 메디치바이오 | 리포-하이드록삼산 유도체 및 이의 약학적 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU34599A (sh) | 1997-01-23 | 2002-03-18 | F. Hoffmann-La Roche Ag. | Inhibitori sulfamid-metaloproteaze |
| US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
| ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
| TR200000368T2 (tr) * | 1997-08-08 | 2000-07-21 | Pfizer Products Inc. | Ariloksiariarilsülfonilamino hidroksamik asit türevleri. |
-
2000
- 2000-08-10 AU AU67644/00A patent/AU6764400A/en not_active Abandoned
- 2000-08-10 AT AT00955435T patent/ATE260251T1/de not_active IP Right Cessation
- 2000-08-10 TR TR2002/02164T patent/TR200202164T2/tr unknown
- 2000-08-10 WO PCT/US2000/021884 patent/WO2001012592A2/en active IP Right Grant
- 2000-08-10 DK DK00955435T patent/DK1210326T3/da active
- 2000-08-10 CA CA002378332A patent/CA2378332A1/en not_active Abandoned
- 2000-08-10 PT PT00955435T patent/PT1210326E/pt unknown
- 2000-08-10 TR TR2002/02211T patent/TR200202211T2/tr unknown
- 2000-08-10 MX MXPA01013324A patent/MXPA01013324A/es active IP Right Grant
- 2000-08-10 US US10/049,544 patent/US6677355B1/en not_active Expired - Fee Related
- 2000-08-10 EP EP00955435A patent/EP1210326B1/en not_active Expired - Lifetime
- 2000-08-10 BR BR0013390-6A patent/BR0013390A/pt not_active IP Right Cessation
- 2000-08-10 DE DE60008548T patent/DE60008548T2/de not_active Expired - Fee Related
- 2000-08-10 TR TR2002/02163T patent/TR200202163T2/tr unknown
- 2000-08-10 JP JP2001516893A patent/JP2003507362A/ja active Pending
- 2000-08-10 TR TR2002/00410T patent/TR200200410T2/tr unknown
- 2000-08-10 ES ES00955435T patent/ES2216938T3/es not_active Expired - Lifetime
- 2000-08-17 CO CO00061938A patent/CO5300407A1/es not_active Application Discontinuation
- 2000-08-17 UY UY26302A patent/UY26302A1/es not_active Application Discontinuation
- 2000-08-17 PE PE2000000833A patent/PE20010486A1/es not_active Application Discontinuation
- 2000-08-17 AR ARP000104249A patent/AR030160A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US6677355B1 (en) | 2004-01-13 |
| TR200202164T2 (tr) | 2002-11-21 |
| CO5300407A1 (es) | 2003-07-31 |
| CA2378332A1 (en) | 2001-02-22 |
| ATE260251T1 (de) | 2004-03-15 |
| EP1210326A2 (en) | 2002-06-05 |
| EP1210326B1 (en) | 2004-02-25 |
| DE60008548T2 (de) | 2004-08-05 |
| AR030160A1 (es) | 2003-08-13 |
| DK1210326T3 (da) | 2004-06-21 |
| ES2216938T3 (es) | 2004-11-01 |
| TR200202211T2 (tr) | 2002-11-21 |
| MXPA01013324A (es) | 2002-07-02 |
| PT1210326E (pt) | 2004-07-30 |
| JP2003507362A (ja) | 2003-02-25 |
| PE20010486A1 (es) | 2001-04-20 |
| UY26302A1 (es) | 2000-10-31 |
| DE60008548D1 (de) | 2004-04-01 |
| WO2001012592A3 (en) | 2001-07-05 |
| AU6764400A (en) | 2001-03-13 |
| TR200202163T2 (tr) | 2002-11-21 |
| WO2001012592A2 (en) | 2001-02-22 |
| BR0013390A (pt) | 2002-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200200410T2 (tr) | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri. | |
| DE60329316D1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| CY1115940T1 (el) | Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων | |
| FI971412A0 (fi) | Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä | |
| SE8804036L (sv) | Ny anvaendning av 11,28-dioxa-4-azatricklo (22.3.1.04.9)-oktakos-18-en-derivat och farmaceutiska kompositioner innehaallande desamma | |
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| ATE448194T1 (de) | Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts | |
| NO984120L (no) | Triarylforbindelser | |
| DE69529690D1 (de) | Diaryl-2(5h)-fuaranone als cox-2-inhibitoren | |
| TR200102072T2 (tr) | İltihap karşıtı maddeler olarak aromatik çok döngülü bileşimler | |
| DE60319066D1 (de) | 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen | |
| TNSN99095A1 (fr) | 4 - phenylpiperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| YU50401A (sh) | Farmaceutski sastav koji sadrži inhibitore protonske pumpe | |
| CY1108992T1 (el) | Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας | |
| DK1030836T3 (da) | Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet | |
| BRPI0410979A (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia | |
| SE0100569D0 (sv) | New compounds | |
| DE602005018390D1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| BR9815596A (pt) | Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase | |
| JP2005506346A5 (tr) | ||
| IS6621A (is) | Þíenódíbensóasúlen efnasambönd sem hindrar fyrir æxlisdrepþátt | |
| BR0315820A (pt) | Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização | |
| EA200500095A1 (ru) | Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств | |
| ATE292117T1 (de) | Zusammensetzungen zur behandlung von hautkrankheiten | |
| AR032553A1 (es) | Derivados de alfa-amino-n-hidroxi-acetamida. |